Trial Profile
Sustained Viral Response Rate in 50 Subjects With Cirrhosis Due to Hepatitis C, Genotype 1, Treated With 12 Weeks of Sofosbuvir, Ledipasvir and Ribavirin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 May 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary) ; Ledipasvir; Ribavirin
- Indications Liver cirrhosis
- Focus Therapeutic Use
- 06 Dec 2017 Status changed from active, no longer recruiting to completed.
- 05 Apr 2017 Planned End Date changed from 1 Jan 2017 to 1 Oct 2017.
- 05 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.